DekaBank Deutsche Girozentrale Trims Stake in Henry Schein, Inc. (HSIC)
DekaBank Deutsche Girozentrale trimmed its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 21.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,350 shares of the company’s stock after selling 6,531 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Henry Schein were worth $4,222,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. NTV Asset Management LLC increased its stake in shares of Henry Schein by 100.0% during the 3rd quarter. NTV Asset Management LLC now owns 3,300 shares of the company’s stock worth $271,000 after purchasing an additional 1,650 shares in the last quarter. Teacher Retirement System of Texas increased its stake in shares of Henry Schein by 176.9% during the 3rd quarter. Teacher Retirement System of Texas now owns 188,507 shares of the company’s stock worth $15,456,000 after purchasing an additional 120,421 shares in the last quarter. Rhumbline Advisers grew its stake in Henry Schein by 100.9% in the 3rd quarter. Rhumbline Advisers now owns 320,162 shares of the company’s stock worth $26,250,000 after acquiring an additional 160,770 shares during the period. Advisor Group Inc. grew its stake in Henry Schein by 276.0% in the 3rd quarter. Advisor Group Inc. now owns 4,801 shares of the company’s stock worth $394,000 after acquiring an additional 3,524 shares during the period. Finally, Moody Lynn & Lieberson LLC grew its stake in Henry Schein by 90.5% in the 3rd quarter. Moody Lynn & Lieberson LLC now owns 6,296 shares of the company’s stock worth $516,000 after acquiring an additional 2,991 shares during the period. Institutional investors own 63.60% of the company’s stock.
Henry Schein, Inc. (NASDAQ HSIC) opened at $67.50 on Tuesday. Henry Schein, Inc. has a 1-year low of $65.28 and a 1-year high of $93.50. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.55 and a quick ratio of 0.86. The company has a market cap of $10,850.00, a price-to-earnings ratio of 19.39, a price-to-earnings-growth ratio of 1.95 and a beta of 1.03.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Monday, November 6th. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. The firm had revenue of $3.16 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the prior year, the firm earned $0.84 EPS. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. equities analysts expect that Henry Schein, Inc. will post 3.6 earnings per share for the current fiscal year.
Henry Schein announced that its board has authorized a stock buyback program on Monday, September 18th that authorizes the company to repurchase $400.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 6.3% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.
HSIC has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Henry Schein from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Robert W. Baird set a $95.00 target price on shares of Henry Schein and gave the stock a “buy” rating in a research note on Thursday, October 19th. Northcoast Research raised shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $109.00 target price for the company in a research note on Monday, August 7th. Stifel Nicolaus lowered their target price on shares of Henry Schein from $89.00 to $77.00 and set a “hold” rating for the company in a research note on Tuesday, November 7th. Finally, Craig Hallum raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $89.88.
In other Henry Schein news, SVP Paul Rose sold 2,126 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $172.51, for a total value of $366,756.26. Following the transaction, the senior vice president now owns 17,841 shares in the company, valued at approximately $3,077,750.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.19% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.